Patient-Level Data: A New Level of Analysis
The new kid on the block is patient-level data. Unlike physician-level data that describes the wholesale activity of Dr. John Smith as writing say 50 scripts of Lipitor, patient-level data zooms in on the patients of Dr. John Smith and specifies patient by patient who actually gets Lipitor.
13th Annual Direct-to-Consumer Rx Marketing & Advertising
PHARMA-MKTING is an exclusive email network for pharmaceutical marketing professionals interested in the latest interactive technologies available for marketing. The network facilitates communication between members and recognized experts and leaders in interactive pharmaceutical marketing.
2nd Annual Forum on Continuing Medical Education
Building on the success of the HIPAA for Drug and Device Companies series, The Institute for International Research is proud to bring you MedPriv 2003. This is the most comprehensive conference that examines all the key medical data privacy laws, offering compliance tactics and strategies across the business operations of drug and device companies.
The Pharma, Biotech and Device Colloquium
The Pharma, Biotech and Device Colloquium, June 6 - 9, 2004, on the Campus of Princeton University Announces Extraordinary Faculty.
Forum on Anonymous Patient-Level Data and Analysis
PHARMA-MKTING is an exclusive email network for pharmaceutical marketing professionals interested in the latest interactive technologies available for marketing. The network facilitates communication between members and recognized experts and leaders in interactive pharmaceutical marketing.
It’s All About Education
What are the differences between promotion and education? This OpEd piece suggests that promotion should be more educational and education should be more promotional and that CME and other educational materials should be part of the typical drug rep's promotional armamentarium.
Evolving CME Regulation: Responding to the Challenges
Dennis D. Elliott, SVP and Managing Director of S.G. Madison & the CBCE, an accredited CME/CE provider, suggested in this presentation that the recent public scrutiny of pharmaceutical support for CME and the various new guidelines and standards may be having a chilling effect on the business of commercial CME providers.
ACCME’s Standards for Commercial Support: Understanding What’s at Stake
A joint presentation by John F. Kamp, Ph.D., J.D., Partner, Wiley, Rein & Fielding and Linda Casebeer, Ph.D., Associate Professor, CME at the University of Alabama School of Medicine, offered a point-counterpoint assessment of ACCME's draft Standards for Commercial Support (SCS) and its effect on the partnership between accredited CME providers and pharmaceutical supporters.
Provider/Pharmaceutical Partnerships – Are They Possible Without Conflict of Interest?
What strategies should a pharmaceutical company follow to ensure a successful partnership with an academic CME provider? What's an appropriate measure for outcomes (ROI)? What % of income from academeic CME programs comes from pharma support?
Provider/Pharmaceutical Partnerships – Are They Possible Without Conflict of Interest?
What strategies should a pharmaceutical company follow to ensure a successful partnership with an academic CME provider? What's an appropriate measure for outcomes (ROI)? What % of income from academeic CME programs comes from pharma support?
